|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using the population based San Francisco Adult Glioma study, we evaluated associations between XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val polymorphisms with glioma risk among white cases (n = 441 to 453) and controls (n = 487 to 526).
|
17898525 |
2007 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A previous study using the RNA microarray technique showed that decrease of MGMT mRNA stands out among the alterations in gene expression caused by the cell growth-depressing transfection of a T98G glioma cell line with liver-type glutaminase (LGA) [Szeliga et al.(2009) Glia, 57, 1014].
|
22888977 |
2012 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation represents a favorable prognostic factor and has been associated with a better response to alkylating agents in glioma and systemic lymphoma.
|
25031012 |
2014 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, the MGMT methylation status determined in the initial glioma tumor did not correlate with the clinical response to temozolomide when this drug was administered as treatment for relapses (P = 0.729).
|
15297393 |
2004 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The objective of this study is to assess the real impact of Io MRI in O-6-methylguanine-DNA methyltransferase and non-O-6-methylguanine-DNA methyltransferase methylated glioma surgery.
|
29309978 |
2018 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The basal promoter in glioma cells with minimal MGMT expression, however, which is 75% unmethylated, was much less accessible, and the basal promoter in nonexpressing cells, which is 50% unmethylated, was entirely inaccessible to restriction enzymes.
|
7523853 |
1994 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
|
21892781 |
2012 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Conventional MRI radiomics models are reliable for predicting the MGMT promoter methylation status in LGG patients.
|
31704598 |
2019 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The present study aimed to reveal the key genes implicated in MGMT promoter methylation in patients with glioma.
|
30535433 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The positive rate of MGMT autoantibody to 20 peptides in glioma groups is compared with healthy individuals, the positive rate of MGMT-02 (45%), MGMT-04 (27%), MGMT-07 (21%), MGMT-10 (13%), and MGMT-18 (24%) were significantly elevated in patients with glioma.
|
31210005 |
2019 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, transferrin nanoparticles encapsulating temozolomide have the potential of a promising anti-tumor strategy against glioma of the O6-methylguanine-DNA-methyltransferase gene promoter methylation.
|
29088799 |
2017 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Whether MGMT promoter methylation correlates with tumor response to temozolomide in low-grade gliomas is less clear.
|
20857319 |
2011 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>FoxD2-AS1</i> is a prognostic factor in glioma and promotes temozolomide resistance in a O<sup>6</sup>-methylguanine-DNA methyltransferase-dependent manner.
|
31680769 |
2019 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q.
|
31745161 |
2019 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the MGMT expression was effectively downregulated by 20(S)-Rg3 via the Wnt/β-catenin pathway in glioma cell lines, and TMZ resistance was significantly reversed by 20(S)-Rg3.
|
30431207 |
2019 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We evaluated the O(6)-methylguanine-DNA methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay.
|
21148162 |
2011 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity.
|
18812520 |
2009 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Interestingly, the risk for glioma was dramatically increased in ionizing radiation exposure individuals who had the wild-type genotypes of MGMT F84L and PARP1 A762V (adjusted odds ratios, 5.95; 95% confidence intervals, 2.21-16.65).
|
19124499 |
2009 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that glioma susceptibility is associated with rs1799782 and rs25487 of X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), rs1805377 of XRCC4, rs1800067 of excision repair cross-complementing rodent repair deficiency complementation group 4 (ERCC4) and rs3212986 of ERCC1 in Asian population, and rs12917 of O-6-methylguanine-DNA methyltransferase (MGMT) and rs1136410 of poly(ADP-ribose) polymerase 1 (PARP1) in Caucasian population.
|
27055523 |
2017 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
|
22390413 |
2012 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioma cells rich in miR-181b were more sensitive to temozolomide. miR-181b expression was not correlated with MGMT promoter methylation status. miR-181b combined with temozolomide enhanced glioma cell sensitivity and apoptosis.
|
23645289 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
|
17721049 |
2007 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.
|
17260000 |
2007 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Active MGMT might have a protective role in LGG tumors, enabling evolution to severe malignancy.
|
28575062 |
2017 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors.
|
24325789 |
2014 |